Figure 1

Dovitinib inhibited the growth and metastasis of HCC in an orthotopic xenograft model. A) Growth of MHCC-97H xenograft tumors was dose-dependently inhibited by dovitinib. The wet liver weight of 0, 25 and 50 mg/kg were 2.00 ± 0.54, 1.68 ± 0.31 and 1.41 ± 0.27 g, respectively. The four largest liver tumors of each group are shown. B) Significant inhibition of SMMC7721 xenograft tumors by dovitinib. The wet liver weight of 0, 25 and 50 mg/kg were 1.87 ± 0.45, 1.63 ± 0.26 and 1.56 ± 0.22 g, respectively. C) Dose-dependent inhibition of QGY-7703 xenograft tumors by dovitinib. The wet liver weight of 0, 25 and 50 mg/kg were 3.44 ± 0.72, 2.59 ± 0.45 and 1.91 ± 0.39 g, respectively. D) For the mice bearing the high-metastasis HCC cell line MHCC-97H, dose-dependent inhibition of lung metastases by dovitinib was observed under a microscope. The arrow points to macro-metastasis; scale bar, 100 μm. The results in panels A-C are expressed as the mean ± the standard deviation. black star, P < 0.05; double black star, P < 0.01.